Physician profile
Gary D Bond
NPI 1053316125
$8,677.92
in general payments reported to CMS, 2019-2025
38 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $583 · 2021: $814 · 2022: $1,116 · 2023: $1,607 · 2024: $2,103 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,432 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,432.18 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $967.90 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals Lp | $942.80 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $936.48 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Travere Therapeutics, INC. | $809.71 | 2019-2025 | |
| Vifor Pharma, INC. | $689.43 | 2019-2024 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $548.49 | 2022-2025 | |
| Novo Nordisk INC | $399.74 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Calliditas Therapeutics US INC. | $373.22 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $301.60 | 2019-2025 | Ultomiris |
| Ardelyx, INC. | $251.77 | 2023-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $215.83 | 2019-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $214.81 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $213.50 | 2019-2023 | Krystexxa |
| Daiichi Sankyo INC. | $213.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.97 | 2023-2025 | Jardiance |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.